{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:41:10Z","timestamp":1774672870904,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T00:00:00Z","timestamp":1276128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Second (2nd)\u2010generation tyrosine kinase inhibitors (TKI) (dasatinib, nilotinib) are effective in patients with all phases of chronic myeloid leukaemia (CML). Dose reductions and treatment interruptions are frequently required due to toxicity, but their significance is unknown. We analysed the impact of dose reductions\/interruptions and dose intensity of 2nd\u2010generation TKI on response and survival. A total of 280 patients with CML (all phases) were analysed. Dose reductions were considered when the daily dose was below the standard dose. Dose intensity was determined based on the percentage of the ideal dose intensity. Overall, 176 patients (63%) required treatment interruptions and\/or dose reduction at least once during therapy. Dose reductions\/interruptions, analysed as a time\u2010dependent covariate, were associated with worse failure\u2010free survival only in patients with untreated CML. Dose intensity analysis did not reveal a worse response or survival in patients who received a lower dose intensity (&lt;100%) during therapy or during the first 6\u2003months. In conclusion, dose reductions and treatment interruptions of 2nd generation TKI in patients with CML have a minimal impact in the response rate and survival of these patients. Further studies are required to determine whether there might be a minimum adequate dose of these agents.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08245.x","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T06:40:19Z","timestamp":1276152019000},"page":"303-312","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical impact of dose reductions and interruptions of second\u2010generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia"],"prefix":"10.1111","volume":"150","author":[{"given":"Fabio P. S.","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianquin","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-191254"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.335.335","article-title":"A Phase III, randomized, open\u2010label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic Myeloid leukemia in chronic phase (CML\u2010CP) using molecular endpoints: 1\u2010year results of TOPS (tyrosine kinase inhibitor optimization and selectivity) study","volume":"112","author":"Cortes J.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2601"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.447.447","article-title":"Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic\u2010phase chronic myeloid leukemia (CML\u2010CP) for 400 mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS]) [abstract]","volume":"112","author":"Guilhot F.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5095"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-161737"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1043.1043","article-title":"Imatinib dose can be safely reduced after complete cytogenetic response (CCyR) in patients (pts) with chronic myeloid leukemia (CML) in early chronic phase (CP) treated with high\u2010dose imatinib [abstract]","volume":"110","author":"Jain N.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3800"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_2_7_21_1","article-title":"AMN107: inhibitory profile against non\u2010mutated and mutated forms of the Bcr\u2010Abl tyrosine kinase [abstract]","volume":"46","author":"Manley P.W.","year":"2005","journal-title":"Proceedings of the American Association for Cancer Research"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.186.186","article-title":"International randomized study of interferon versus STI571 (IRIS) 7\u2010year follow\u2010up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [abstract]","volume":"112","author":"O\u2019Brien S.G.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.050"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.LBA-1.LBA-1","article-title":"Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial [abstract]","volume":"114","author":"Saglio G.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.38.38","article-title":"Dasatinib (BMS\u2010354825) in patients with chronic myeloid leukemia (CML) and philadelphia\u2010chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: update of a phase i study [abstract]","volume":"106","author":"Sawyers C.L.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11863"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4687"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093617"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3187.3187","article-title":"CML Patients with Low OCT\u20101 activity achieve better molecular responses on high dose imatinib than on standard dose. those with high OCT\u20101 activity have excellent responses on either dose: a TOPS correlative study [abstract]","volume":"112","author":"White D.L.","year":"2008","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1111\/j.1365-2141.2011.08909.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T00:00:00Z","timestamp":1318377600000}}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08245.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08245.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:41:25Z","timestamp":1697431285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08245.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,12]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08245.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08245.x","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1111\/j.1365-2141.2011.08909.x","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,12]]},"assertion":[{"value":"2010-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}